

Anti-CD19 Chimeric Antigen Receptor Targeting  
of CD19+ Acute Myeloid Leukemia

Gina Ma, Yi Wang, Tahmeena Ahmed, Ann-Leslie  
Zaslav, Laura Hogan, Cecilia Avila, Masayuki  
Wada, Huda Salman



PII: S2213-0489(17)30072-9  
DOI: <https://doi.org/10.1016/j.lrr.2018.03.002>  
Reference: LRR136

To appear in: *Leukemia Research Reports*

Received date: 15 December 2017  
Revised date: 23 February 2018  
Accepted date: 18 March 2018

Cite this article as: Gina Ma, Yi Wang, Tahmeena Ahmed, Ann-Leslie Zaslav, Laura Hogan, Cecilia Avila, Masayuki Wada and Huda Salman, Anti-CD19 Chimeric Antigen Receptor Targeting of CD19+ Acute Myeloid Leukemia, *Leukemia Research Reports*, <https://doi.org/10.1016/j.lrr.2018.03.002>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Anti-CD19 Chimeric Antigen Receptor Targeting of CD19+ Acute Myeloid Leukemia

Gina Ma<sup>a1</sup>, Yi Wang<sup>b1</sup>, Tahmeena Ahmed<sup>b</sup>, Ann-Leslie Zaslav<sup>b</sup>, Laura Hogan<sup>c</sup>, Cecilia Avila<sup>d</sup>, Masayuki Wada<sup>a</sup>, Huda Salman<sup>e\*</sup>

<sup>a</sup>iCell Gene Therapeutics LLC, Research & Development Division, Long Island High Technology Incubator, 25 Health Science Drive, Stony Brook, NY 11790

<sup>b</sup>Department of Pathology, Stony Brook Medicine, Stony Brook, NY 11794

<sup>c</sup>Department of Pediatrics, Stony Brook Children's Hospital, Stony Brook University Medical Center, Stony Brook, NY 11794

<sup>d</sup>Department of OB-GYN, Stony Brook Medicine, Stony Brook University Medical Center Stony Brook, NY 11794

<sup>e</sup>Department of Internal Medicine, Stony Brook Medicine, Stony Brook University Medical Center, Stony Brook, NY 11794

\*Correspondence: Dr. Huda Salman. Stony Brook Medicine, 101 Nicolls Road, Stony Brook, NY 11794, USA. E-mail: [huda.salman@stonybrookmedicine.edu](mailto:huda.salman@stonybrookmedicine.edu)

Keywords: T cells, immunotherapy, acute myeloid leukemia, mixed phenotype acute leukemia, and chimeric antigen receptors

### Abstract:

Aberrant expression of CD19 in acute myeloid leukemia (AML) is commonly associated with t(8;21)(q22;q22), although AML cases lacking this translocation occasionally express CD19. Mixed-phenotype acute leukemia also frequently expresses CD19. Chimeric antigen receptor (CAR) technology is a major breakthrough for cancer treatment, with the recent approval of CD19-directed CAR (CD19CAR) for treating B-cell malignancies. However, little information exists on using CD19CAR for other CD19 positive neoplasms such as AML. Our findings indicate that CD19CAR therapy can potentially be used for those with mixed phenotype leukemia and a subset of AML cases.

### Introduction

---

<sup>1</sup> These authors contributed equally to this work.

Download English Version:

<https://daneshyari.com/en/article/8453531>

Download Persian Version:

<https://daneshyari.com/article/8453531>

[Daneshyari.com](https://daneshyari.com)